Company Filing History:
Years Active: 2016
Title: Innovations in Cancer Immunotherapy by Fernanda V V Castro
Introduction
Fernanda V V Castro is an accomplished inventor based in Monrovia, California. She has contributed significantly to the field of cancer research through her innovative work in developing therapeutic compositions for cancer immunotherapy. With one patent to her name, her contributions are paving the way for new methods to combat tumor-derived immunosuppression.
Latest Patents
Fernanda's sole patent is titled "Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy." This patent describes a single modality cancer immunotherapy regimen that incorporates a therapeutic composition. The composition can consist of a strain featuring a plasmid that expresses an shRNA molecule designed to suppress the expression of various immunosuppressive targets, ultimately inhibiting tumor growth. Key targets include STAT3, IDO1, IDO2, Arginase 1, iNOS, CTLA-4, TGF-β, IL-10, pGE2, or VEGF, with specific emphasis on IDO1 or Arg1, utilizing shRNA molecules identified as SEQ ID NO:5-14.
Career Highlights
Fernanda is currently affiliated with City of Hope, a renowned research institution specializing in medical research and treatment. Her work focuses on advancing cancer immunotherapy, making substantial strides toward enhancing patient outcomes. Her dedication and innovative spirit have earned her recognition in the scientific community, underscoring the importance of her contributions to cancer research.
Collaborations
In her career, Fernanda has collaborated with prominent colleagues, including Don Jeffrey Diamond and Edwin Manuel. These partnerships facilitate the exchange of knowledge and expertise, enhancing the development of innovative solutions to combat cancer.
Conclusion
Fernanda V V Castro stands out as a pioneering inventor in the realm of cancer immunotherapy. Her patent and associated research highlight the potential for innovative approaches in treating cancer, specifically through disrupting tumor-derived immunosuppression. As she continues her work at City of Hope, her contributions may lead to groundbreaking advancements in cancer treatment that can significantly improve patient care and survival rates.